von Willebrand disease (VWD) is a bleeding disorder caused by either quantitative (type 1 and 3) or qualitative (type 2) defects of von Willebrand factor (VWF). No single available test provides appropriate information about the various functions of VWF, and the laboratory diagnosis of VWD is based on a panel of tests, including the measurement of factor VIII coagulant activity (FVIIIC), VWF antigen levels (VWF:Ag), VWF activity as measured by the ristocetin co-factor activity (VWF:RCo), the collagen-binding activity of VWF (VWF:CB), VWF multimer analysis, ristocetininduced platelet agglutination (RIPA), the factor-VIII-binding assay of plasma VWF and VWF propeptide levels. Due to the heterogeneity of VWF defects and the variables that interfere with VWF levels, a correct diagnosis of types and subtypes may sometimes be difficult, but is very important for therapy. Furthermore, the RCo assay and the RIPA test are based on platelet agglutination in reaction with the non-physiological antibiotic ristocetin. These tests also have low sensitivity and are difficult to standardise. Therefore, several analyses (tests) are required to diagnose VWD and it is important to be aware of the pitfalls to which these tests are subjected in terms of the diagnosis. In this article, the laboratory diagnosis of patients with type 1, 2A, 2B, 2M, 2N and 3 VWD will be explained by using a modified algorithm that was first proposed by the guidelines for diagnosis and treatment of VWD in Italy. Therefore, it is important to diagnose patients with an increased clearance rate of VWF. Platelet-type VWD (PT-VWD) is a rare autosomal-dominant bleeding disorder. The genetic defect is in platelets rather than VWF, and the disease is characterised by abnormally high binding affinity of the platelets to the VWF, similar to type 2B VWD. 4 Therefore, most people with PT-VWD are misdiagnosed as type 2B VWD. However, these may require different therapeutic management, so discrimination is clinically important. The spectrum and severity of VWD is wide, ranging from a few doubtful haemorrhagic symptoms to severe life-threatening bleeding episodes. This is due not only to the heterogeneous VWF gene,
Laboratory Diagnosis of von Willebrand Disease

Sample Collection
Blood samples must be collected into tubes containing 0.105M sodium citrate in a ratio of 1:9 with blood. Platelet-poor plasma (PPP) is prepared by centrifugation of whole blood at 2,000g for 20 minutes at room temperature. Samples must be stored immediately after centrifugation in polypropylene tubes at -70ºC until analysed. It is important to note that a cryoprecipitate may form if plasma samples are stored at temperatures over -70ºC. Cryoprecipitate contains large quantities of VWF, especially HMW multimers. 8 All tests must be performed on original aliquots that were not previously thawed, and plasma samples should be thawed to 37ºC before performing the diagnostic tests. Special care should be taken to ensure that no cryoprecipitate is present in the samples; therefore, it must be dissolved before the tests are performed as it will influence the results. 8 
Screening Tests
Screening tests for bleeding disorders include a platelet count, a bleeding time, prothrombin time (PT) and activated partial thromboplastin time (APTT), plasma FVIII levels and the blood group of a patient. These tests are usually carried out by a routine coagulation laboratory.
Laboratory Tests
The first line of tests includes the VWF concentration in plasma (VWF:Ag), the ristocetin co-factor assay (VWF:RCo) and the collagen binding assay (VWF:CB The ristocetin-induced platelet agglutination (RIPA) and the VWF multimer patterns are performed to diagnose the type 2 subtypes.
RIPA is measured by mixing different concentrations of ristocetin ranging from 0.2 to 2mg/ml in increments of 0.1mg/ml with the patient's PRP in an aggregometer. The results are expressed as the concentration of ristocetin (mg/ml) able to induce 30% agglutination.
RIPA-mixing studies are performed to distinguish between type 2B
VWD and PT-VWD. In short, the patient's PRP and PRP from a control pattern is determined using a gel-documentation system. 15 VWF multimer patterns from normal plasma and type 1, 2A, 2B and 2M VWD is shown in Figure 2 and the density graphs in Figure 3 . 
Diagnosis of von Willebrand Disease
The algorithm used for the laboratory diagnosis of VWD is outlined in 
Conclusion
We have outlined a systematic way to diagnose VWD. This algorithm is also recommended by the International Society for Thrombosis and Haemostasis (ISTH). It is important to note that the RCo/Ag ratio and the CB/Ag ratio are necessary to distinguish between type 1 and type 2 VWD.
The CBA is extremely sensitive in the discrimination of type 1 and types 2A and 2B VWD. 11 In contrast, however, the RCo test has a poor sensitivity of 50%, 18 which is difficult to standardise, 19 and lacks a physiological analogue; however, it remains the standard method for The mechanisms involved in type 1 VWD include reduced synthesis and secretion of VWF or increased clearance of VWF from plasma. 20 In patients with increased clearance of VWF, the DDAVP treatment would not be effective, as VWF in plasma is cleared from the circulation very quickly. The ratio between the propeptide and the antigen levels is used as an indication of VWF clearance in these patients. 3 The RIPA test is necessary to distinguish between type 2B and type 2A
VWD. It is also important to carry out the RIPA test with ristocetin concentrations ranging from 0.2 to 2mg/ml in increments of 0.1mg/ml.
This will ensure a range of concentrations to determine the maximum agglutination value of 30%. Currently, the RIPA test that is being used by most laboratories in developing countries is performed with only three ristocetin concentrations (0.5, 1 and 1.25mg/ml In conclusion, it is crucial to use a systematic method to diagnose VWD. Each laboratory test only forms one piece of the diagnostic puzzle and therefore it is necessary to put all of the puzzle pieces together for the whole diagnostic picture to emerge. ■
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